Chin Laura D, AbuHilal Mohn'd
Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.
Division of Dermatology, Department of Medicine, McMaster University, Hamilton, ON, Canada.
SAGE Open Med Case Rep. 2020 May 6;8:2050313X20919614. doi: 10.1177/2050313X20919614. eCollection 2020.
Ocrelizumab is a humanized monoclonal antibody that targets the CD20 antigen found on B-cells. It is indicated in the treatment of both relapsing-remitting multiple sclerosis and primary progressive multiple sclerosis.
The aim of this study is to report and describe the characteristics of alopecia areata following treatment with ocrelizumab for multiple sclerosis.
Five patients were reported, two female and three male. Four of the five patients had alopecia areata of the scalp, one of the five having alopecia to the beard area. All patients responded well to conventional treatment with topical and intralesional corticosteroids and topical minoxidil foam. Ocrelizumab can be associated with the development of alopecia areata. Initiation of proper treatment may lead to quick improvement or resolution of this potentially reversible adverse effect.
奥瑞珠单抗是一种靶向B细胞上CD20抗原的人源化单克隆抗体。它被用于治疗复发缓解型多发性硬化症和原发性进行性多发性硬化症。
本研究的目的是报告并描述奥瑞珠单抗治疗多发性硬化症后斑秃的特征。
报告了5例患者，其中2例女性，3例男性。5例患者中有4例出现头皮斑秃，5例中有1例出现胡须部位脱发。所有患者对局部和病灶内注射皮质类固醇以及局部外用米诺地尔泡沫的常规治疗反应良好。奥瑞珠单抗可能与斑秃的发生有关。开始适当治疗可能会使这种潜在可逆的不良反应迅速改善或消退。
